Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Cytori stem cell therapy ECCS-50 enters phase III trial in male urinary incontinence

Sep. 8, 2015

Sanofi terminates option to license Ardelyx's RDX-002 program

Sep. 4, 2015

CSIR scientists describe PDE5A inhibitors

Aug. 21, 2015

FDA approves Procysbi for children aged 2-6 years with nephropathic cystinosis

Aug. 18, 2015

First patients randomized in phase IIa trial of SER-150 in diabetic nephropathy

Aug. 17, 2015

Proteon initiates second phase III study of vonapanitase

Aug. 17, 2015

Daiichi Sankyo discloses compounds for hyperphosphatemia

Aug. 13, 2015

Relypsa signs new patiromer agreements

Aug. 12, 2015

FDA accepts NDA for ZS-9 in hyperkalemia

July 30, 2015

Phase III extension studies show long-term benefit of NX-1207 in BPH

July 29, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...